Reinfection of Nine-Valent Human Papillomavirus Vaccine Types Among HIV-Negative Men Who Have Sex With Men: A Prospective Cohort Study

Lirong Liu 1,2, Guozhen Zhang 1, Zewen Zhang 1, Lu Wang 1, Duolao Wang 3 and Jianghong Dai 1*

1 Department of Epidemiology and Biostatistics, School of Public Health, Xinjiang Medical University, Urumqi, China, 2 Center for Disease Control and Prevention of Yining, Yining, China, 3 Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom

Objectives: Reinfection of human papillomavirus (HPV) among men who have sex with men (MSM) after clearing the infection of HPV has not been well characterized. To understand the reinfection of HPV among human immunodeficiency virus (HIV) negative MSM without HPV vaccine, we analyzed the reinfection of nine-valent HPV vaccine (9v-HPV) types.

Methods: Data were acquired from a prospective cohort study among HIV-negative MSM in Urumqi of Xinjiang from 1 April 2016 to 14 July 2020. Participants were recruited through a local non-government organization using a website advertisement. Self-administered questionnaires and self-collected anal swabs were collected at baseline and every 6 months. The incidence rates of reinfection was calculated based on the number of events divided by person-months of observation of event risk. 95% confidence intervals (CIs) were calculated based on the Poisson distribution.

Results: A total of 515 HIV-negative unvaccinated MSM were included with a mean age of 30.93 years (SD 7.85), and 27.68% were reinfected with any 9v-HPV type after clearance. The reinfection incidence rate of any 9v-HPV was 14.47 per 1000 person-months (95% CI: 11.52–17.87). HPV52 was the most common type of reinfection, with a reinfection rate of 17.96 per 1000 person months (95% CI: 11.58–26.33). Univariate analysis showed that MSM over the age of 30 had a slightly higher risk of reinfection with any 9v-HPV (Hazard ratio (HR): 1.57; 95% CI: 1.01–2.45), but no significant association was observed in multivariate analysis.

Conclusions: Our study showed MSM without HPV vaccine will become reinfected following the natural clearance of specific HPV types. It is also suggested that HPV vaccination is recommended not only prior to sexual debut but also after viral clearance for MSM to reduce HPV prevalence.

Keywords: reinfection, human papillomavirus, men who have sex with men, nine-valent vaccine-preventable HPV, HIV-negative
INTRODUCTION

Human papillomaviruses (HPVs) are one of the most common sexually transmitted viruses in men and women. Because of their frequent high-risk sexual behaviors, men who have sex with men (MSM) are at increased risk for anal HPV infection and HPV-related diseases (1–3), while persistent infection might induce precancerous lesions and cancers (4). The estimated prevalence of anal HPV among human immunodeficiency virus (HIV) negative MSM in China was 53.6%, and the most frequently detected HPV genotypes were HPV6, HPV16, HPV11, HPV52, and HPV58 (5–7). Several prophylactic HPV vaccines have been available since 2006, such as HPV-16/18 bivalent vaccine (Cervarix®, GSK, and Cecolin®, Xiamen Innovax), HPV-6/11/16/18 quadrivalent vaccine (Gardasil®, Merck), and HPV-6/11/16/18/31/33/45/52/58 nine-valent vaccine (Gardasil®9, Merck). However, in many countries, including China, vaccination of HPV is still primarily directed at women (8).

Host immune responses are likely to be a critical mechanism for preventing, controlling, and eliminating HPV infection (9). However, because antibody concentrations after prophylactic HPV vaccination are higher than those observed after natural HPV infection (10), whether these naturally acquired antibodies protect against future infections has been debated in earlier studies (11–13). Studies on the natural history of HPV infection among women have shown that individuals may be susceptible to redetection of HPV infection with the same HPV type (1–3), while persistent infection might induce precancerous lesions and cancers (4). The estimated prevalence of anal HPV among human immunodeficiency virus (HIV) negative MSM in China was 53.6%, and the most frequently detected HPV genotypes were HPV6, HPV16, HPV11, HPV52, and HPV58 (5–7). Several prophylactic HPV vaccines have been available since 2006, such as HPV-16/18 bivalent vaccine (Cervarix®, GSK, and Cecolin®, Xiamen Innovax), HPV-6/11/16/18 quadrivalent vaccine (Gardasil®, Merck), and HPV-6/11/16/18/31/33/45/52/58 nine-valent vaccine (Gardasil®9, Merck). However, in many countries, including China, vaccination of HPV is still primarily directed at women (8).

Study visits took place every 6 months. Participants completed a self-administered questionnaire at baseline and each follow-up visit, designed to collect information on sociodemographic and sexual behavior characteristics. Participants also self-collected anal swabs and then placed them into a 3 ml sample transport medium for testing. To improve the accuracy of sampling, volunteers from non-government organization were trained by clinicians before the study, and volunteers then instructed the participants to collect anal specimens during the study. All participants were compensated Chinese ¥40 (~$6.6) at each visit.

MSM, who had received no previous dose of HPV vaccine and attended at least three visits by 14 July 2020 were included in this study. The participants provided written informed consent. This study was approved by the ethics committee of the First Affiliated Hospital of Xinjiang Medical University (20160512-11).

METHODS

Study Design and Participants

We have established a dynamic prospective cohort study of HPV research among HIV-negative MSM in Urumqi, Xinjiang, China from 1 April 2016. Participants were recruited through a local non-government organization (Xinjiang Dream Health Service Center) using website advertisement, a WeChat group (an extremely popular social application), and peer recommendations. Men were eligible to participate if they (1) were at least 18-years-old; (2) self-reported having sex with men in the past 6 months; and (3) were HIV-negative.

In this prospective cohort study, we analyzed the reinfection of anal 9 HPV vaccine types (HPV-6/11/16/18/31/33/45/52/58) among HIV-negative MSM without HPV vaccine in Urumqi, China. Our objective was to estimate reinfection of anal nine-valent HPV vaccine (9v-HPV) types of MSM.

Variables and Definitions

Sociodemographic variables of interest included age, education, registered residence, ethnicity, marital, employment status, and average monthly income. Sexual behaviors included age of first anal intercourse, self-reported sexual orientation, the gender of sexual partners, experience of anal intercourse in the past 6 months, pattern of anal intercourse in the past year, number of sexual partners in the past 6 months, number of anal sex encounters in the last week, drug use, STD infection in the past year, smoking status, and alcohol consumption.

To study reinfections with a given HPV type, clearance of the infection was defined as a negative test result of the same HPV type after the positive detection of an HPV type (1–0). The reinfection was defined as the positive detection again of the same HPV type after being cleared of an HPV type (1–0-1). In a sensitivity analysis, we used a conservative definition of clearance that required at least two consecutive negative samples (1–0-0). This stricter definition is evaluated by considering that a single negative visit between two positives may be due to the DNA content in the sample being below the threshold of detectability. Clearance of bivalent HPV (2v-HPV) types of infection was defined as a negative test result of both HPV16 and HPV18 after the positive detection of HPV16 or/and HPV18. Reinfection of any 2v-HPV was defined as the positive detection again of HPV16 or/and HPV18 after clearance of 2v-HPV types. Any
860 MSM Recruited April 9, 2016, to July 14, 2020

7 MSM incomplete information at baseline:
  3 MSM without behavior information;
  4 MSM without valid HPV samples

853 MSM at baseline

338 MSM less than 3 visits

515 MSM included in study

339 MSM infected with any 9v-HPV type during study

289 MSM cleared 9v-HPV type infection

80 MSM reinfected with any 9v-HPV type

**FIGURE 1** | Flowchart of human immunodeficiency virus (HIV)-negative men who have sex with men (MSM) for the study. MSM, men who have sex with men; HIV, human immunodeficiency virus; HPV, human papillomavirus; 9v-HPV, nine-valent HPV types, such as HPV6, 11, 16, 18, 31, 33, 45, 52, and 58.
quadrivalent HPV (4v-HPV) type (HPV6/11/16/18) and any 9v-HPV (HPV6/11/16/18/31/33/45/52/58) data were defined in the same way.

**Statistical Analyses**

Descriptive statistics included the mean and standard deviation (SD) or median and interquartile range (IQR) for continuous variables, frequency, and percentages for categorical variables. The incidence rates of reinfection, including 95% confidence intervals (CIs), were calculated based on the number of events divided by the time of event risk observed. The time to risk of reinfection events was the time in a month from the first clearance to the date that the subject first tested re-positive for a given HPV type in subsequent follow-up. Each HPV infection was treated as an independent event in the study. The 95% CIs were calculated based on the Poisson distribution. A Cox proportional hazards model was used to analyze the factors associated with reinfection. The variables with \( p < 0.20 \) in the univariate analyses and the influencing factors reported in the literature were included in the multivariate Cox proportional hazards model to determine the factors associated with HPV reinfections. Data analysis was performed using R version 4.0.2.

**RESULTS**

Between 9 April 2016, and 14 July 2020, a total of 860 HIV-negative MSM without HPV vaccine were recruited in the study, of whom 515 provided at least three visits with qualified samples for HPV testing included in the study (4 without valid samples for HPV testing at baseline, 3 without a behavior information questionnaire at baseline, and 338 with <three visits were excluded). The median duration of follow-up was 31.50 months (IQR 22.77–37.80), and the median number of follow-up visits was 6 times (IQR 4–7). Among 515 MSM, a total of 393 (76.31%) had any 9v-HPV infection during the study, natural clearance occurred in 73.54% (289/393). In total, 27.68% (80/289) were reinfected with any 9v-HPV after clearance (Figure 1).

**Participant Baseline Characteristics**

The mean age of the 515 MSM at enrolment was 30.93 years (SD 7.85). At baseline, a total of 396 (76.89%) identified themselves as homosexual and 409 (79.42%) reported having had the experience of anal intercourse in the past 6 months. A total of 259 (50.29%) had one and more than one sexual partner in the past 6 months and only 92 (17.86%) had one and more than one time of anal sex encounter in the last week. The demographic and sexual behaviors baseline characteristics of 515 MSM are reported in Table 1.

The prevalence at baseline of any 2v-HPV, any 4v-HPV, and any 9v-HPV type was 11.26% (58/515), 26.02% (134/515), and 35.53% (183/515), respectively (Figure 2). HPV6 (64, 12.43%) had a higher prevalence, followed by HPV16 (44, 8.54%) (Figure 2).

**Reinfection Incidence Rate**

The incidence rate of reinfection of any 9v-HPV was 14.47 per 1,000 person-months (95% CI: 11.52–17.87). The incidence rate of reinfections varied substantially by HPV type. The reinfection
rate was highest for HPV52 (rate 17.96 per 1,000 person-months, 95% CI: 11.58–26.33) and lowest for HPV45 (rate 1.59 per 1,000 person-months, 95% CI: 0.99–6.99). HPV6 (26 participants) and HPV16 (25 participants) had a higher number of reinfected individuals compared to other types, the reinfection rate was 9.64 per 1,000 person-months (95% CI: 6.39–13.83) and 11.58 per 1,000 person-months (95% CI: 7.61–16.73), respectively. The reinfection incidence rate of each HPV type is shown in Table 2.

**Risk Factors of Any 9v-HPV Reinfection**

Table 3 lists the factors associated with any 9v-HPV reinfection among HIV-negative unvaccinated MSM. In univariate analyses, MSM over the age of 30 had a slightly higher risk of reinfection with any 9v-HPV [Hazard ratio (HR): 1.57; 95% CI: 1.01–2.45], but no significant association was observed in the multivariate analysis.

**Sensitivity Analyses**

After a conservative definition of clearance, we analyzed the reinfection rate of any 9v-HPV, any 4v-HPV, any 2v-HPV, and type-specific HPV. The conservative reinfection rate of any 9v-HPV was 13.09 per 1,000 person-months (95% CI: 8.53–19.05). Except for HPV45 which no conservative reinfection was observed, the rate of conservative reinfection for the other 8 types ranged from 6.57 per 1,000 person-months for HPV18 (95% CI: 1.09–20.28) to 23.04 per 1,000 person-months for HPV52 (95% CI: 10.53–42.89). For most HPV types, the rate of conservative reinfection was higher than reinfection (Table 4).

**DISCUSSION**

Our results showed that 27.68% of HIV-negative unvaccinated MSM will be reinfected after natural clearance of a specific HPV type, and the reinfection rate of any 9v-HPV was 14.47 per 1,000 person-months (95% CI: 11.52–17.87). HPV52 had the highest reinfection incidence rate of all specific HPV types. HPV6 and HPV16 had a higher number of reinfected individuals compared to other types.

There are fewer studies on anal HPV reinfection in MSM, which limits the comparison of our findings with other studies. Only one study on genital recurrence in men found that the recurrence of HPV infections was 20%, and HPV types 58, 52, 18, and 16 had the highest rates of recurrence (18). Similar to our study, the reinfection of 9v-HPV was 27.68%, and HPV52 had the highest reinfection rate. Reinfections of HPV were also reported in the few studies conducted among women. In a study by Krings et al. among women, 21.2% had acquired new high-risk infections with other genotypes after clearance of the original infection (19).
TABLE 2 | Incidence rates* of reinfection of human papillomavirus (HPV) among HIV-negative MSM (N = 515).

| Type        | Infected number (%) | Cleared number (%) | Reinfected number (%) | Person-months at risk | Rate (95% CI) |
|-------------|---------------------|--------------------|-----------------------|-----------------------|---------------|
| 9v-HPV      | 393 (76.31)         | 289 (73.54)        | 80 (27.68)            | 5,529.77              | 14.47 (11.52–17.87) |
| 4v-HPV      | 335 (65.05)         | 254 (75.82)        | 55 (21.65)            | 5,101.48              | 10.78 (8.18–13.89) |
| 2v-HPV      | 185 (35.92)         | 136 (78.72)        | 11 (8.09)             | 3,151.95              | 3.49 (1.81–5.96)   |
| HPV6        | 171 (33.20)         | 135 (78.95)        | 26 (19.26)            | 2,697.57              | 9.64 (6.39–13.83)  |
| HPV11       | 104 (20.19)         | 84 (80.77)         | 19 (22.62)            | 1,686.14              | 11.27 (6.93–17.12) |
| HPV16       | 140 (27.18)         | 103 (73.57)        | 25 (24.27)            | 2,159.22              | 11.58 (7.61–16.73) |
| HPV18       | 73 (14.17)          | 54 (73.97)         | 6 (11.11)             | 1,213.17              | 4.95 (1.97–10.02)  |
| HPV21       | 59 (11.46)          | 48 (81.36)         | 10 (20.83)            | 1,085.45              | 9.21 (4.62–16.16)  |
| HPV33       | 67 (13.01)          | 47 (70.15)         | 10 (21.28)            | 975.01                | 10.26 (6.14–17.99) |
| HPV45       | 39 (7.57)           | 27 (69.23)         | 1 (3.70)              | 629.57                | 1.59 (0.09–6.99)   |
| HPV52       | 102 (19.81)         | 73 (71.57)         | 23 (31.51)            | 2,803.40              | 17.96 (11.58–26.33) |
| HPV58       | 94 (18.25)          | 78 (82.98)         | 22 (28.21)            | 1,470.49              | 14.96 (9.55–22.11) |

**Table 2** | Factors associated reinfection of any nine-valent HPV types (9v-HPV) at baseline (N = 289).

| Variable                                          | Univariate | Multivariate |
|---------------------------------------------------|------------|--------------|
|                                                   | HR (95%CI) | P            | HR (95%CI) | P |
| Age (years)                                       |            |              |            |   |
| ≤30                                               | Ref        |              |            |   |
| >30                                               | 1.57 (1.01–2.45) | 0.045        | 1.35 (0.81–2.25) | 0.224 |
| Marital status                                    |            |              |            |   |
| Single                                            | Ref        |              |            |   |
| Married/divorced                                  | 1.30 (0.96–1.75) | 0.085        | 1.11 (0.78–1.57) | 0.573 |
| Self-reported sexual orientation                  |            |              |            |   |
| Homosexual                                        | 0.66 (0.42–1.04) | 0.074        | 0.69 (0.43–1.10) | 0.118 |
| Bisexual/heterosexual                             | Ref        |              |            |   |
| Experience of anal intercourse in the past 6 months|            |              |            |   |
| Yes                                               | 1.55 (0.82–2.93) | 0.178        | 1.38 (0.70–2.72) | 0.346 |
| No                                                | Ref        |              |            |   |
| Number of sexual partners in the past 6 months    |            |              |            |   |
| ≥1                                                | 1.35 (0.86–2.12) | 0.192        | 1.19 (0.74–1.93) | 0.478 |
| <1                                                | Ref        |              |            |   |

*Per 1,000 person-months.

MSM, men who have sex with men; HPV, human papillomavirus; CI, confidence interval; 9v-HPV, nine-valent HPV types, including HPV6, 11, 16, 18, 31, 33, 45, 52, and 58; 4v-HPV, quadrivalent HPV types, including HPV6, 11, 16, and 18; 2v-HPV, bivalent HPV types, including HPV16 and HPV18.

A study by Moscicki et al. observed redetection of HPV-16 DNA in 18.1% of women (14). In a study of young women, 19.4% of incident infections of multiple genotypes were redetected within a year (15). However, in our study, the reinfection rates of specific HPV types were higher than in adult women (16). It is important to note that previous studies on the prevalence of HPV infection vary in different populations and geographical regions, such as the prevalence of HPV infection being higher in HIV-negative men than in HIV-negative women (3), making comparisons between studies difficult.

A study found that rather than inducing protective immunity, HPV infection strongly increases the risk of a future infection by the same type, by investigating HPV transmission dynamics by fitting mechanistic models to data from unvaccinated men (20). Research of Sofie H. Mooij also shows no evidence for a protective effect of naturally induced HPV antibodies on subsequent anogenital HPV infection in MSM (13). As men appear not to develop immunity to HPV following natural infection, the reinfection HPV type will likely depend on the prevalence of the individual HPV types circulating in the community. Studies have reported that the most common high-risk HPV type among HIV-negative MSM were HPV52, 58, 16, and 18 (5, 6, 21–24). Therefore, it is understandable that HPV types 58, 52, and 16 had the highest rates of reinfection in our study. Since HPV16 is the most common HPV type associated with cancers (25, 26), the result of the highest number of HPV16 reinfection individuals in our study should be noted. Vaccine efficacy trials have shown that the vaccination of children before the first sex can significantly reduce the infection rate, and vaccination of previously infected individuals can also reduce the prevalence of HPV (27–30). Thus, early vaccination of MSM with the HPV vaccine is important to prevent HPV prevalence.

Moreover, the risk of HPV infection depends on differences in demographic and behavioral risk factors between populations. For example, HIV positivity and a higher number of sexual partners can increase the rate of HPV infection and persistent infection (31–34). Patterns of anal intercourse, a history of condom use during homosexual behaviors, and drug use were reported to be the main factors influencing HPV infection (35, 36). In our study, univariate analysis showed that MSM over the age of 30 had a slightly higher risk of reinfection with any 9v-HPV, but no significant association was observed in multivariate analysis. Epidemiological studies worldwide have found two peaks of HPV infection in women. The first occurs a few years
TABLE 4 | Incidence rates* of reinfection and conservative reinfection of specific HPV types among HIV-negative MSM (N = 515).

| Type     | Reinfection | Conservative Reinfection |
|----------|-------------|-------------------------|
|          | Person-months at risk | Rate (95% CI) | Person-months at risk | Rate (95% CI) |
| 9v-HPV   | 289          | 80 (27.68)         | 5,529.77       | 14.47 (11.52–17.87) | 186          | 24 (12.90)        | 1,833.43       | 13.09 (8.53–19.05) |
| 4v-HPV   | 254          | 55 (21.65)         | 5,101.48       | 10.78 (8.18–13.89) | 176          | 20 (11.38)        | 1,613.70       | 12.39 (7.72–18.65) |
| 2v-HPV   | 136          | 11 (8.09)          | 3,151.95       | 3.49 (1.81–5.98)   | 99           | 7 (7.07)          | 1,015.21       | 6.90 (2.96–13.33)  |
| HPV6     | 135          | 26 (19.26)         | 2,697.57       | 9.64 (6.39–13.83)  | 97           | 8 (8.25)          | 881.52         | 9.06 (4.15–16.89)  |
| HPV11    | 84           | 19 (22.62)         | 1,686.14       | 11.27 (6.93–17.12) | 63           | 8 (12.70)         | 610.36         | 13.11 (5.99–24.40) |
| HPV16    | 103          | 25 (24.27)         | 2,159.22       | 11.58 (7.61–16.73) | 76           | 13 (17.11)        | 760.30         | 17.10 (9.41–28.15) |
| HPV18    | 54           | 6 (11.11)          | 1,213.17       | 4.95 (1.97–10.02)  | 39           | 2 (5.13)          | 304.31         | 6.57 (1.09–20.28)  |
| HPV31    | 48           | 10 (20.83)         | 1,085.45       | 9.21 (4.62–16.16)  | 37           | 4 (10.81)         | 313.14         | 12.77 (3.96–29.67) |
| HPV33    | 47           | 10 (21.28)         | 975.01         | 10.26 (5.14–17.99) | 35           | 6 (17.14)         | 424.50         | 14.13 (5.62–28.64) |
| HPV45    | 27           | 1 (3.70)           | 629.57         | 1.59 (0.09–6.99)   | 16           | 0 (0.00)          | 132.42         | /               |
| HPV52    | 73           | 23 (31.51)         | 1,280.80       | 17.96 (11.58–26.33) | 40           | 8 (20.00)         | 347.15         | 23.04 (10.53–42.89) |
| HPV58    | 78           | 22 (28.21)         | 1,470.49       | 14.96 (9.55–22.11) | 52           | 6 (11.54)         | 547.60         | 10.96 (4.35–22.20) |

*Per 1,000 person-months.

MSM, men who have sex with men; HIV, human immunodeficiency virus; HPV, human papillomavirus; CI, confidence interval; 9v-HPV, nine-valent HPV types, including HPV6, 11, 16, 18, 31, 33, 45, 52, and 58; 4v-HPV, quadrivalent HPV types, including HPV6, 11, 16, and 18, and 2v-HPV, bivalent HPV types, including HPV16 and HPV18.

After sexual debut, and the second peak occurs around the time of menopause (37). There are two main theories to explain this occurrence: (1) a new sexual partner or an increased number of sexual partners; and (2) reactivation of latent infections acquired many years earlier (38). In earlier studies, the prevalence of HPV among MSM did not reveal an obvious peak phenomenon. In contrast, a study showed that seroprevalence increased with age among young-to-middle-aged men with significant upward age trends observed for HPV 11, 16, and 18 (39). This finding may be related to the number of new sexual partners. With an increase in age, the proportion of women with more than one sexual partner will decline, whereas the proportion of MSM remains at a relatively stable level (40). Unfortunately, there are currently not enough numbers in our study to do an analysis by age. With the implementation of our cohort study, we should understand the relationship between the number of sexual partners and HPV reinfection in different age groups, to further clarify the true situation of age, the number of sexual partners, and HPV reinfection.

STRENGTHS AND LIMITATIONS

To our knowledge, this is the first study to characterize the reinfection of anal HPV among HIV-negative MSM in China. Important limitations associated with this study should be recognized. First, we did not distinguish between HPV reactivation and reinfection. In our future studies, we can use next-generation sequencing to shed light on the origin of the reinfections. Second, the negative results of a subsequent sample after infection were considered to indicate cleared, without considering that the DNA content in the sample may be below the threshold of detectability, which may increase the number of events cleared. However, we still found similar results after using the conservative definition of clearance, which improves the credibility of this research results. We must also be aware of the impact of a small number of reinfection events on the stability of results.

CONCLUSION

In conclusion, our study found a high rate of anal 9v-HPV reinfections among HIV-negative unvaccinated MSM. Therefore, HPV vaccination is recommended not only prior to sexual debut but also after viral clearance for MSM to reduce HPV prevalence. Moreover, future studies are needed to understand the role of reinfection in the etiology of HPV-associated diseases.
DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University (20160512-11). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

LL and ZZ: data curation. LL, GZ, ZZ, and LW: material preparation and data collection. LL and GZ: analyzed and interpreted the data. LL: original draft of the manuscript. JD and GZ: funding acquisition. DW: polished and reviewed the language of the main article. All authors have read and agreed to the published version of the manuscript.

ACKNOWLEDGMENTS

We thank Xinjiang Dream Health Service Center for recruitment and data collection.

REFERENCES

1. Marra E, Kovaleva A, Bruisten SM, Vermeulen W, Boyd A, Schim van der Loeff MF. Incidence and clearance of anal high-risk human papillomavirus infections and their determinants over 5 years among human immunodeficiency virus-negative men who have sex with men. Clin Infect Dis. (2019) 68:1556–65. doi: 10.1093/cid/ciy738
2. Alberts CJ, Heard I, Canestri A, Marchand L, Fléjou JF, Piroth L, et al. Incidence and clearance of anal human papillomavirus (HPV)-16 and HPV-18 infection, and their determinants, among human immunodeficiency virus-infected men who have sex with men in France. J Infect Dis. (2020) 221:1488–93. doi: 10.1093/infdis/jiz623
3. Lin C, Franceschi S, Clifford GM. Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis. Lancet Infect Dis. (2018) 18:198–206. doi: 10.1016/S1473-3099(17)30653-9
4. De Sanjose S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. (2018) 47:2–13. doi: 10.1016/j.bpobyn.2017.08.015
5. Zhou Y, Lin YF, Gao L, Dai J, Luo G, Li L, et al. Human papillomavirus prevalence among men who have sex with men in China: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. (2021) 40:1357–67. doi: 10.1007/s10096-021-04229-y
6. Fan S, Li P, Ouyang L, Yuan T, Gong H, Ding Y, et al. Anal human papillomavirus infection among MSM attending university in China: implications for vaccination. Vaccines. (2020) 8:175. doi: 10.3390/vaccines8020175
7. Nowak RG, Gravitt PE, He X, Ketende S, Dauda W, Omuhi H, et al. Prevalence of anal high-risk human papillomavirus infections among HIV-positive and HIV-negative men who have sex with men in Nigeria. Sex Transm Dis. (2016) 43:243–8. doi: 10.1097/OLQ.0000000000000431
8. Harper DM, DeMars LR. HPV vaccines - a review of the first decade. Gynecol Oncol. (2017) 146:196–204. doi: 10.1016/j.ygyno.2017.04.004
9. Stanley MA, Sterling JC. Host responses to infection with human papillomavirus. Curr Probl Dermatol. (2014) 45:58–74. doi: 10.1159/000355964
10. Harper DM, Franco EL, Wheeler C, Ferriss DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like-particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. (2004) 364:1757–65. doi: 10.1016/S0140-6736(04)17398-4
11. Lu B, Hagensee ME, Lee JH, Wu Y, Stockwell HG, Nielson CM, et al. Epidemiologic factors associated with seropositivity to human papillomavirus type 16 and 18 virus-like particles and risk of subsequent infection in men. Cancer Epidemiol Biomarkers Prev. (2010) 19:511–6. doi: 10.1158/1055-9966.EPI-09-0790
12. Beachler DC, Jenkins G, Safaean M, Kreimer AR, Wentzensen N. Natural acquired immunity against subsequent genital human papillomavirus infection: a systematic review and meta-analysis. J Infect Dis. (2016) 213:1444–54. doi: 10.1093/infdis/jiv753
13. Mooij SH, Landén O, van der Kliis FR, van der Sande MA, de Melker HE, Coutinho RA, et al. No evidence for a protective effect of naturally induced HPV antibodies on subsequent anogenital HPV infection in HIV-negative and HIV-infected MSM. J Infect. (2014) 69:375–86. doi: 10.1016/j.jinf.2014.06.003
14. Moscicki AB, Ma Y, Farhat S, Darragh TM, Pawlita M, Galloway DA, et al. Redetection of cervical human papillomavirus type 16 (HPV16) in women with a history of HPV16. J Infect Dis. (2013) 208:403–12. doi: 10.1093/infdis/jit175
15. Winer RL, Hughes JP, Feng Q, Xi LF, Cherne S, O’Reilly S, et al. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev. (2011) 20:699–707. doi: 10.1158/1055-9965.EPI-10-1108
16. Trottier H, Ferreira S, Thomann P, Costa MC, Sobrinho JS, Prado JC, et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res. (2010) 70:8569–77. doi: 10.1158/0008-5472.CAN-10-0621
17. Tian T, Miijti P, Bingxue H, Fadong Z, Ainwaer A, Guoyao S, et al. Prevalence and risk factors of anal human papillomavirus infection among HIV-negative men who have sex with men in Urumqi City of Xinjiang Uygur autonomous region, China. PLoS ONE. (2017) 12:e0187928. doi: 10.1371/journal.pone.0187928
18. Pammnani SJ, Sudenga SL, Rollison DE, Ingles DJ, Abrahamsen M, Villa LL, et al. Recurrence of genital infections with 9 human papillomavirus (HPV) vaccine types (6, 11, 16, 18, 31, 33, 45, 52, and 58) among men in the HPV infection in men (HIM) study. J Infect Dis. (2018) 218:1219–27. doi: 10.1093/infdis/jiy300
19. Krings A, Boahteng G, Dunyo P, Amuah JE, Adams RA, Adunyame L, et al. Dynamics of genotype-specific HPV clearance and reinfection in rural Ghana may compromise HPV screening approaches. Papillomavirus Res. (2019) 7:45–51. doi: 10.1016/j.pvr.2018.12.004
20. Ranjeva SL, Baskerville EB, Dukic V, Villa LL, Lazcano-Ponce E, Giuliano AR, et al. Recurrence of HPV infection with ecologically distinct HPV types can explain high prevalence and diversity. Proc Natl Acad Sci USA. (2017) 114:13573–8. doi: 10.1073/pnas.1714712114
21. Tuan LA, Prem K, Pham QD, Toh ZQ, Tran HP, Nguyen PD, et al. Anal human papillomavirus prevalence and risk factors among men who have sex with men in Vietnam. Int J Infect Dis. (2021) 112:136–43. doi: 10.1016/j.ijid.2021.09.016
Prevalence of human papillomavirus (HPV) by geographical regions, sexual orientation and HIV status in China: a systematic review and meta-analysis. *Sex Transm Infect.* (2018) 94:434–42. doi: 10.1136/sextrans-2017-053412

Marra E, Lin C, Clifford GM. Type-specific anal human papillomavirus infection among men, according to sexual preference and HIV status: a systematic literature review and meta-analysis. *J Infect Dis.* (2019) 29:590–8. doi: 10.1093/infdis/jiy556

Shanmugasundaram S, You J. Targeting persistent human papillomavirus infection. *Viruses.* (2017) 9:229. doi: 10.3390/v9080229

Grulich AE, Poynten IM, Machalek DA, Jin F, Templeton DJ, Hillman RJ. The epidemiology of anal cancer. *Sex Health.* (2012) 9:504–8. doi: 10.1071/SH12070

Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. *New England J Med.* (2011) 364:401–11. doi: 10.1056/NEJMoa0909537

Mikamo H, Yamagishi Y, Murata S, Yokokawa R, Han SR, Wakana A, et al. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: a randomized, phase 3, placebo-controlled study. *Vaccine.* (2019) 37:1651–8. doi: 10.1016/j.vaccine.2019.01.069

Meites E, Winer RL, Newcomb ME, Gorbach PM, Querec TD, Rudd J, et al. Vaccine effectiveness against prevalent anal and oral human papillomavirus infection among men who have sex with men—United States, 2016–2018. *J Infect Dis.* (2020) 222:2052–2060. doi: 10.1093/infdis/jiaa306

Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *N Engl J Med.* (2011) 365:1576–85. doi: 10.1056/NEJMoa1010971

Nadar HJ, van Bilsen WPH, Marra E, Bruisten S, Heideman DAM, Schim van der Loef MF. Incidence and clearance of penile high-risk HPV infection and their determinants among HIV-negative men who have sex with men. *Sex Transm Dis.* (2021) 48:886–72. doi: 10.1097/OLQ.0000000000001455

Méndez-Martínez R, Maldonado-Frias S, Vázquez-Vega S, Caro-Vega Y, Rendón-Maldonado JG, Guido-Jiménez M, et al. High prevalent human papillomavirus infections of the oral cavity of asymptomatic HIV-positive men. *BMC Infect Dis.* (2020) 20:990–1002. doi: 10.1186/s12879-019-4677-9

Niyitray AG, Fujimoto K, Zhao J, Giuliano AR, Schneider JA, Hwang LY. Prevalence of and risk factors for anal human papillomavirus infection in a sample of young, predominantly black men who have sex with men, Houston, Texas. *J Infect Dis.* (2018) 217:777–84. doi: 10.1093/infdis/jix617

Supindham T, Chariyalertsak S, Utsaipat U, Miura T, Ruanpeng D, Chotirosniramat N, et al. High prevalence and genotype diversity of anal HPV infection among MSM in Northern Thailand. *PLoS ONE.* (2015) 10:e0124499. doi: 10.1371/journal.pone.0124499

Gatechompol S, Teeratakulpisarn N, Wittawatmongkol O, Teeraananchai S, Kerr SJ, Chalermchokchareonkit A, et al. Incidence, persistence, and factors associated with HPV infection among male adolescents with and without perinatally acquired HIV infection. *J Acquir Immune Defic Syndr.* (2020) 85:553–60. doi: 10.1097/QAI.0000000000002499

Zhou Y, Lin YF, Meng X, Duan Q, Wang Z, Yang B, et al. Anal human papillomavirus among men who have sex with men in three metropolitan cities in southern China: implications for HPV vaccination. *Vaccine.* (2020) 38:2849–58. doi: 10.1016/j.vaccine.2020.02.009

Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. *J Infect Dis.* (2010) 202:1789–99. doi: 10.1086/657321

Roehr B. Presence of HPV in later life may represent reactivation, not reinfection. *BMJ (Clinical Researched).* (2012) 345:e8517. doi: 10.1136/bmj.e8517

Lu B, Viscidi RP, Lee JH, Wu Y, Villa LL, Lazcano-Ponce E, et al. Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV infection in men study (him study). *Cancer Epidemiol Biomarkers Prev.* (2011) 20:990–1002. doi: 10.1158/1055-9965.EPI-10-1160

Poynten IM, Machalek D, Templeton D, Jin F, Hillman R, Zablotszka I, et al. Comparison of age-specific patterns of sexual behaviour and anal HPV prevalence in homosexual men with patterns in women. *Sex Transm Infect.* (2016) 92:228–31. doi: 10.1136/sextrans-2015-052032

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Liu, Zhang, Zhang, Wang, Wang and Dai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.